{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"103.01","value":"96.2"},{"groupId":"OG001","spread":"131.87","value":"67.7"},{"groupId":"OG002","spread":"125.18","value":"59.3"},{"groupId":"OG003","spread":"47.88","value":"34.2"},{"comment":"As the mean is 0, standard deviation is not applicable.","groupId":"OG004","spread":"NA","value":"0.0"},{"groupId":"OG005","spread":"210.73","value":"200.7"},{"groupId":"OG006","spread":"540.27","value":"376.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"}],"units":"Participants"}],"description":"All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days \\[96 hours\\]))","dispersionType":"Standard Deviation","groups":[{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week.","id":"OG000","title":"Arm 2, Group X (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week.","id":"OG001","title":"Arm 2, Group X (45 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week.","id":"OG002","title":"Arm 2, Group X (60 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week.","id":"OG003","title":"Arm 2, Group X (80 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week.","id":"OG004","title":"Arm 2, Group Y (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week.","id":"OG005","title":"Arm 2, Group Y (45 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.","id":"OG006","title":"Arm 2, Group Y (60 mg)"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (with available samples for analysis)","reportingStatus":"POSTED","timeFrame":"Post dose to pre-dose (up to 3.5 years)","title":"Highest Percent Change of Fetal Hemoglobin From Baseline in Arm 2 (MWF Every Other Week)","type":"SECONDARY","unitOfMeasure":"Percent Change"}